- Recommendation ID
- TA214/1
- Question
- Further research designed to investigate differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior taxane exposure, would be particularly useful.
- Any explanatory notes
(if applicable) - None.
Source guidance details
- Comes from guidance
- Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
- Number
- TA214
- Date issued
- February 2011
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |